SØG - mellem flere end 8 millioner bøger:
Viser: Anticancer Treatments and Cardiotoxicity - Mechanisms, Diagnostic and Therapeutic Interventions
Anticancer Treatments and Cardiotoxicity Vital Source e-bog
Patrizio Lancellotti
(2016)
Anticancer Treatments and Cardiotoxicity
Mechanisms, Diagnostic and Therapeutic Interventions
Patrizio Lancellotti, Jose L. Zamorano og Maurizio Galderisi
(2016)
Sprog: Engelsk
Detaljer om varen
- Vital Source searchable e-book (Reflowable pages)
- Udgiver: Elsevier Science (November 2016)
- ISBN: 9780128026472
Anticancer Treatments and Cardiotoxicity: Mechanisms, Diagnostic and Therapeutic Interventions presents cutting edge research on the adverse cardiac effects of both radiotherapy and chemotherapy, brought together by leaders in the field. Cancer treatment-related cardiotoxicity is the leading cause of treatment-associated mortality in cancer survivors and is one of the most common post-treatment issues among survivors of adult cancer. Early detection of the patients prone to developing cardiotoxicity, taking in to account the type of treatment, history and other risk factors, is essential in the fight to decrease cardiotoxic mortality.
This illustrated reference describes the most effective diagnostic and imaging tools to evaluate and predict the development of cardiac dysfunction for those patients undergoing cancer treatment. In addition, new guidelines on imaging for the screening and monitoring of these patients are also presented. Anticancer Treatments and Cardiotoxicity is an essential reference for those involved in the research and treatment of cardiovascular toxicity.
- Provides algorithms essential for the use of imaging, and biomarkers for the screening and monitoring of patients
- Written by world-leading experts in the field of cardiotoxicity
- Includes high-quality images, case studies, and test questions
- Describes the most effective diagnostic and imaging tools to evaluate and predict the development of cardiac dysfunction for those patients undergoing cancer treatment
Bookshelf online: 5 år fra købsdato.
Bookshelf appen: ubegrænset dage fra købsdato.
Udgiveren oplyser at følgende begrænsninger er gældende for dette produkt:
Print: -1 sider kan printes ad gangen
Copy: højest -1 sider i alt kan kopieres (copy/paste)
Detaljer om varen
- Hardback: 470 sider
- Udgiver: Elsevier Science & Technology (December 2016)
- Forfattere: Patrizio Lancellotti, Jose L. Zamorano og Maurizio Galderisi
- ISBN: 9780128025093
Anticancer Treatments and Cardiotoxicity: Mechanisms, Diagnostic and Therapeutic Interventions presents cutting edge research on the adverse cardiac effects of both radiotherapy and chemotherapy, brought together by leaders in the field. Cancer treatment-related cardiotoxicity is the leading cause of treatment-associated mortality in cancer survivors and is one of the most common post-treatment issues among survivors of adult cancer. Early detection of the patients prone to developing cardiotoxicity, taking in to account the type of treatment, history and other risk factors, is essential in the fight to decrease cardiotoxic mortality.
This illustrated reference describes the most effective diagnostic and imaging tools to evaluate and predict the development of cardiac dysfunction for those patients undergoing cancer treatment. In addition, new guidelines on imaging for the screening and monitoring of these patients are also presented. Anticancer Treatments and Cardiotoxicity is an essential reference for those involved in the research and treatment of cardiovascular toxicity.
- Provides algorithms essential for the use of imaging, and biomarkers for the screening and monitoring of patients
- Written by world-leading experts in the field of cardiotoxicity
- Includes high-quality images, case studies, and test questions
- Describes the most effective diagnostic and imaging tools to evaluate and predict the development of cardiac dysfunction for those patients undergoing cancer treatment
1. Epidemiology and Trend of Prognosis in Cancer Patients
2. Categories of Anticancer Treatments
3. Classification by Mechanisms of Cardiotoxicity
4. Cardiotoxicity of Oncologic Treatments: Is There a Uniform Definition?
5. The Impact of Radiotherapy Section II: Detrimental Effects of Anticancer Drugs and Radiotherapy on the Heart
6. Lessons From Preclinical Models
7. Genetic and Epigenetic Risk Factors
8. Changes of Myocardial Structure and Function
9. Alteration of Heart Valves
10. Pericardial Damage
11. Effects of Radiotherapy on Vessels and Coronary Arteries
12. Cardiac Conduction Disturbances Section III: Cardiovascular Complications of Cancer Treatments
13. Cardiac Rhythm Disturbances
14. Acute and Chronic Heart Failure
15. Coronary Artery Disease
16. Pericardial Effusion and Pericarditis
17. Radiation-Induced Carotid Atherosclerosis
18. Valvular Heart Disease
19. Atrial Fibrillation and Stroke in Cancer Patients Section IV: Imaging Evaluation of Cardiac Structure and Function in Cancer Patients
20. The Role of Echocardiography
21. The Role of Cardiovascular Magnetic Resonance (CMR)
22. Nuclear Medicine Imaging and Cardiotoxicity Section V: Detection of Cardiac Dysfunction and Predictors of Cardiotoxicity
23. Detection by Cardiac Imaging: LV Ejection Fraction, Diastolic Dysfunction, Tissue Doppler, and Speckle Tracking Echocardiography
24. The Role of Biomarkers: Troponins, BNP, MPO, and Other Biomarkers
25. Screening and Comprehensive Follow-Up Evaluation
26. Preoperative Assessment for Noncardiac Surgery Section VI: Cardiotoxicity in Childhood
27. Cardiotoxicity of Childhood Cancer Treatments Section VII: Management of Anticancer Drugs Related Cardiotoxicity
28. Nonpharmacologic Therapy
29. Beta-Blockers
30. Angiotensin-Converting Enzyme Inhibition
31. Diuretics
32. Antiarrhythmic Drugs
33. Anticoagulation in Cancer Patients
34. New Drugs: The Beneficial Effects of Ranolazine
35. Percutaneous Coronary Intervention and Cardiac Surgery in Cancer Patients
36. Focus on the Patient With Known Cardiac Disease
37. Multidisciplinary Approach to Cardiac Disease in Cancer Patients Section VIII: Future Research Priorities
38. Pharmacogenomics Screening
39. Cardiac Monitoring During Clinical Trials
40. Preventive Therapy
41. Cardiotoxicity: Future Research Directions
Handler du som firma
Forretningsbetingelser
Porto og forsendelse
Data & cookiepolitik
Tlf 77 42 43 44 - email poly@polyteknisk.dk - CVR 34072655 - Sydbank Reg: 6748 Konto 0001107927